TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25901097

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lifestyle modification and intensive medical management (LS/IMM)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) and Lifestyle modification and intensive medical management (LS/IMM)
Number of subjects: 68
Study: 22431305

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 111
Study: 21952346

Group type: EXPERIMENTAL
Intervention: 3-in-1 perineal care washcloth impregnated with 3% dimethicone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Water and pH neutral soap (control)
Number of subjects: 141
Study: 19250003

Group type: EXPERIMENTAL
Intervention: Intravenous micronutrient therapy (IVMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (lactated Ringer's solution)
Number of subjects: 34
Study: 17827929

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg daily for 48 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg daily for 48 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 12
Study: 14644064

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11479846

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) in patients who underwent GCP
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electrogastrography (EGG) in normal subjects
Number of subjects: 25
Study: 8151592

Group type: EXPERIMENTAL
Intervention: specially trained physical therapists (PT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: traditional physical therapists (PT)
Number of subjects: 54
Study: 2901818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 30
Study: 29160551

Group type: EXPERIMENTAL
Intervention: Pilates group (n=20)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Yoga group (n=18)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Isometric group (n=18)
Number of subjects: 56
Study: 28061372

Group type: EXPERIMENTAL
Intervention: Beat gestures present during word recall
Number of subjects: 106

Group type: COMPARATOR
Intervention: No beat gestures present during word recall
Number of subjects: 106
Study: 26019023

Group type: EXPERIMENTAL
Intervention: Low-fat spread enriched with plant sterols (PS) and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at doses of 0.0, 0.9, 1.3, and 1.8 g/day for 4 weeks
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 282
Study: 22366739

Group type: COMPARATOR
Intervention: GT with skimmed milk (GT + M)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GT with caseinate (GT + CS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GT with soy protein (GT + S)
Number of subjects: 24
Study: 21452357

Group type: EXPERIMENTAL
Intervention: Active PEMF treatment (pulsing electromagnetic field) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham PEMF treatment (identical sham transducers) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both active and sham PEMF treatments.
Number of subjects: 99
Study: 18472364

Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiation therapy (IMRT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Stereotactic radiation/cyberknife (SRT/CBK)
Number of subjects: 132

Group type: COMPARATOR
Intervention: First booster dose (46-70 Gy)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Dose in the superior constrictor muscle
Number of subjects: 132
Study: 16864841

Group type: EXPERIMENTAL
Intervention: DMS48 visual recognition memory test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of high-risk patients for Alzheimer's disease (AD)
Number of subjects: 0
Study: 12658089

Group type: EXPERIMENTAL
Intervention: Planned phacoemulsification (PEA) with IOL insertion after PKP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triple procedure: Penetrating keratoplasty (PKP) and extracapsular cataract extraction (ECCE) with IOL insertion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 10739508

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate increased to 2 mg after 6 months with 2.5 mg medroxyprogesterone acetate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate increased to 2 mg after 6 months with 5 mg medroxyprogesterone acetate
Number of subjects: 419
Study: 9256140

Group type: EXPERIMENTAL
Intervention: M‐CSF (8 x 10(6) U/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 8353925

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 666
Study: 3658907

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (2 l/min overnight from 22 hrs to 6 hrs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study: 29808033

Group type: EXPERIMENTAL
Intervention: Systolic BP during follow-up
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Diastolic BP during follow-up
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Mean BP during follow-up
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Systolic BP and Diastolic BP during follow-up
Number of subjects: 3147
Study: 26803525

Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST) with a 70% threshold value of maximal expiratory pressure, using an EMST device, 5 days a week for 4 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo group trained with a sham device.
Number of subjects: 27
Study: 26329473

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low fructose diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 72
Study: 22625182

Group type: EXPERIMENTAL
Intervention: Complementary Feeding Group (CFG) - received ICDS plus WHO recommendations on breastfeeding and complementary foods.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Responsive Complementary Feeding and Play Group (RCF&PG) - received the same intervention as CFG plus skills for responsive feeding and psychosocial stimulation.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control Group (CG) - received routine Integrated Child Development Services (ICDS).
Number of subjects: 600
Study: 21148267

Group type: EXPERIMENTAL
Intervention: Insole shoe wedge and augmented pressure sensor (I-ShoWS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment programme
Number of subjects: 35
Study: 18186995

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 microg one puff once daily and as required (active group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Budesonide 200 microg one puff twice daily plus their own short‐acting beta(2)‐agonist as required (control group)
Number of subjects: 71
Study: 16603852

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg each night)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12741624

Group type: EXPERIMENTAL
Intervention: ABC
Number of subjects: 18

Group type: COMPARATOR
Intervention: ABC+3TC
Number of subjects: 18
Study: 11115733

Group type: EXPERIMENTAL
Intervention: Acute antipsychotic drug administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison group (maintained on APDs)
Number of subjects: 21
Study: 8833207

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg, intravenously)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clodronate (1500 mg, intravenously)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ibandronate (0.5-2 mg, intravenously)
Number of subjects: 43
Study: 8365276

Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion (washed RBCs autotransfused)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (washed cells discarded)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 2427904

Group type: EXPERIMENTAL
Intervention: Low-molecular weight dextran 40 (Thomaedex 40)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 40/05 (Expafusin)
Number of subjects: 0
Study: 29705445

Group type: EXPERIMENTAL
Intervention: Bitter orange (500 mg capsules)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lavender (500 mg capsules)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (500 mg capsules containing starch)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Bitter orange vs Lavender
Number of subjects: 156
Study: 30417105

Group type: EXPERIMENTAL
Intervention: Healthy default sides
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy default beverages
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy default sides in quick-service restaurants
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy default beverages in quick-service restaurants
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy default sides in table-service restaurants
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy default beverages in table-service restaurants
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Healthy defaults
Number of subjects: 145
Study: 24529610

Group type: EXPERIMENTAL
Intervention: Gradual switch to iloperidone
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Immediate switch to iloperidone
Number of subjects: 500

Group type: COMPARATOR
Intervention: Both gradual and immediate switch groups
Number of subjects: 500
Study: 22644009

Group type: EXPERIMENTAL
Intervention: Glycophosphopeptical (1 g every 8 hours for 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glycophosphopeptical
Number of subjects: 38
Study: 21102963

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of 6 mg non-particulate Celestone
Number of subjects: 140
Study: 19337408

Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated cytarabine (DepoCyte)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15671101

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: CHO-rich diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: SFA-rich diet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 59
Study: 14765609

Group type: EXPERIMENTAL
Intervention: Fluoridated bonding agent with fluoridated composite resin (Group III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non‐fluoridated bonding agent with fluoridated composite (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoridated bonding agent with non‐fluoridated composite (Group I)
Number of subjects: 60
Study: 10391396

Group type: EXPERIMENTAL
Intervention: Captopril (100 mg) alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Captopril (100 mg) in combination with bendrofluazide (2.5 mg)
Number of subjects: 11
Study: 8897080

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 24
Study: 1706501

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg/day (group A)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 111
Study: 6472606

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological testing
Number of subjects: 0
Study: 31387894

Group type: EXPERIMENTAL
Intervention: Linear load pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonlinear load pressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Conventional respiratory physiotherapy)
Number of subjects: 40
Study: 29361335

Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Number of subjects: 1499

Group type: COMPARATOR
Intervention: 150 μg/kg ivermectin
Number of subjects: 1499
Study: 26071564

Group type: EXPERIMENTAL
Intervention: SCL-90-R (Symptom Checklist) assessment for psychological distress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCL-90-R assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 0
Study: 23680969

Group type: EXPERIMENTAL
Intervention: Removable partial dental prostheses (RPDP)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Shortened dental arch (SDA)
Number of subjects: 215
Study: 22455549

Group type: EXPERIMENTAL
Intervention: Long-pulsed diode laser with a large spot size and vacuum-assisted suction
Number of subjects: 35
Study: 20363840

Group type: EXPERIMENTAL
Intervention: Withdrawal of mechanical ventilation
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Number of organ failures
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Vasopressors
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: IV fluids
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Surgical vs medical service
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1505
Study: 18318924

Group type: EXPERIMENTAL
Intervention: Telemedicine system
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 1500
Study: 15759454

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metformin 1000 mg/day
Number of subjects: 83
Study: 11954669

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention based on the Progressively Lowered Stress Threshold (PLST) model
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 241
Study: 10027371

Group type: EXPERIMENTAL
Intervention: Prevertebral gastric tube reconstruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrosternal gastric tube reconstruction
Number of subjects: 60
Study: 7732693

Group type: COMPARATOR
Intervention: 30% of individual maximal physical working capacity (PWC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50% of individual maximal physical working capacity (PWC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (30% and 50% intensity)
Number of subjects: 30
Study: 2201940

Group type: EXPERIMENTAL
Intervention: Complete and timely course of antenatal glucocorticoids
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Partial course of antenatal glucocorticoids
Number of subjects: 223

Group type: COMPARATOR
Intervention: No glucocorticoids
Number of subjects: 223
Study: 7046699

Group type: EXPERIMENTAL
Intervention: Flurazepam 15mg daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31141445

Group type: EXPERIMENTAL
Intervention: Medicine ball plyometric training (8 weeks, thrice per week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 31842937

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention package including training in occupational health, formation of workplace committees, health and safety plan promotion, and provision of face-masks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 28587520

Group type: EXPERIMENTAL
Intervention: Internet adaptation of an evidence-based infant parenting intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25830446

Group type: EXPERIMENTAL
Intervention: Experimental intervention (RAISE‐ETP)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study: 23836967

Group type: EXPERIMENTAL
Intervention: Wii Fit training (3 times a week for 3 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal activities (Control)
Number of subjects: 12
Study: 21590273

Group type: EXPERIMENTAL
Intervention: 0.6 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.9 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.2 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 10
Study: 19594937

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily (QD)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 100 microg twice daily (BID)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate metered dose inhaler (BDP-MDI) 168 microg BID
Number of subjects: 233
Study: 17577003

Group type: EXPERIMENTAL
Intervention: 54 mg of genistein daily for 24 months
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 15028450

Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pharmacologic castration
Number of subjects: 48
Study: 11380968

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transrectal ultrasound
Number of subjects: 65
Study: 9726277

Group type: EXPERIMENTAL
Intervention: Sustained-release naltrexone (NTX) 206 mg subcutaneous injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 20
Study: 8277105

Group type: EXPERIMENTAL
Intervention: GAU intervention for rehabilitation classification
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: GAU intervention for medical-surgical classification
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: GAU intervention for both classifications
Number of subjects: 155
Study: 2690599

Group type: EXPERIMENTAL
Intervention: Experimental NHS nursing homes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10439

Group type: EXPERIMENTAL
Intervention: Antirheumatic drugs
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Pain response measured using a daily pain chart
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Patients' satisfaction rating
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Mean number of days withdrawn
Number of subjects: 684
Study: 31282059

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVX)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (GXN)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXN)
Number of subjects: 13
Study: 27053574

Group type: EXPERIMENTAL
Intervention: Structured patient education ambulatory program combined with weekly sessions of dance therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Structured patient education ambulatory program
Number of subjects: 67
Study: 25095738

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with clopidogrel (75 mg) plus aspirin (300 mg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Aspirin monotherapy (300 mg)
Number of subjects: 325
Study: 23358123

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW) 2 mg
Number of subjects: 295
Study: 21970467

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease participants
Number of subjects: 387

Group type: COMPARATOR
Intervention: Cognitively healthy controls
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Nursing home residents with Alzheimer's disease
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease participants living at home
Number of subjects: 387
Study: 19349892

Group type: EXPERIMENTAL
Intervention: Noncultured keratinocyte/melanocyte cosuspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17400593

Group type: EXPERIMENTAL
Intervention: HAMLET (surgical decompression)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PAIS (Paracetamol in Stroke)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HAMLET and PAIS (informed consent appreciation)
Number of subjects: 60
Study: 15200749

Group type: EXPERIMENTAL
Intervention: 5 mg zoledronic acid intravenously yearly
Number of subjects: 1714

Group type: COMPARATOR
Intervention: Placebo infusion yearly
Number of subjects: 1714
Study: 11489699

Group type: EXPERIMENTAL
Intervention: Chronic prostatitis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Chronic bacterial prostatitis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison with controls
Number of subjects: 46
Study: 9728832

Group type: EXPERIMENTAL
Intervention: Scalp infiltration with bupivacaine (0.25%) and epinephrine (1:200,000)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline/epinephrine (1:200,000)
Number of subjects: 36
Study: 7826961

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (verum)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5% human albumin (placebo)
Number of subjects: 64